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Abstract
Background. Microtubes (MTs), cytoplasmic extensions of glioma cells, are important cell communication struc-
tures promoting invasion and treatment resistance through network formation. MTs are abundant in chemoresistant 
gliomas, in particular, glioblastomas (GBMs), while they are uncommon in chemosensitive IDH-mutant and 1p/19q 
co-deleted oligodendrogliomas. The aim of this study was to identify potential signaling pathways involved in MT 
formation.
Methods. Bioinformatics analysis of TCGA was performed to analyze differences between GBM and oligodendro-
glioma. Patient-derived GBM stem cell lines were used to investigate MT formation under transforming growth 
factor-beta (TGF-β) stimulation and inhibition in vitro and in vivo in an orthotopic xenograft model. RNA sequencing 
and proteomics were performed to detect commonalities and differences between GBM cell lines stimulated with 
TGF-β.
Results. Analysis of TCGA data showed that the TGF-β pathway is highly activated in GBMs compared to oligo-
dendroglial tumors. We demonstrated that TGF-β1 stimulation of GBM cell lines promotes enhanced MT formation 
This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://
creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, 
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and communication via calcium signaling. Inhibition of the TGF-β pathway significantly reduced MT forma-
tion and its associated invasion in vitro and in vivo. Downstream of TGF-β, we identified thrombospondin 
1 (TSP1) as a potential mediator of MT formation in GBM through SMAD activation. TSP1 was upregulated 
upon TGF-β stimulation and enhanced MT formation, which was inhibited by TSP1 shRNAs in vitro and in 
vivo.
Conclusion. TGF-β and its downstream mediator TSP1 are important mediators of the MT network in GBM 
and blocking this pathway could potentially help to break the complex MT-driven invasion/resistance 
network.
Key Points
• TGF-β signaling is upregulated in GBM compared to chemosensitive 
oligodendroglioma.
• TGF-β promotes MT formation in GBM cells and increases calcium exchange and 
invasion.
• SMAD signaling and TSP1 are downstream mediators of TGF-β induced MT 
formation.
Microtubes (MTs) are cytoplasmatic extensions of glioblas-
toma (GBM) cells that form a connective network leading 
to increased invasion and promoting resistance to radio-
therapy.1 The formation of MTs is heterogeneous and more 
pronounced in a subpopulation of invasive and stem-like 
GBM cells.1,2 Growth Associated Protein 43 (GAP43), a pro-
tein involved in neurite sprouting, was identified as an im-
portant mediator involved in the structural development of 
MTs. Intercellular calcium waves were detected as a way 
of communication through the MT network and Connexin 
43, a major gap junction protein, was found to be function-
ally involved.1 The MT network was observed extensively 
in GBM and also in astrocytic tumors in general, however, 
was scarce in oligodendroglioma. These 2 tumor types can 
be distinguished at the molecular level by IDH mutation 
and 1p/19q co-deletion, which are only present in oligo-
dendroglioma.3 In contrast to GBMs and astrocytomas, 
oligodendroglioma patients show remarkable responses to 
radio- and chemotherapy and therefore have a much better 
prognosis.4 Thus, to identify mechanisms of MT formation 
in GBM and to unravel how MTs promote cell-to-cell com-
munication might ultimately lead to a better understanding 
of therapeutic resistance and new ways of GBM treatment. 
Interestingly, a recent study showed that network formation 
of MTs was enhanced in the resection cavity after neu-
rosurgery in experimental models.5 MT formation in this 
context might partly explain why recurrent tumors often de-
velop close to the resection site. Recently, it was shown that 
glioma cells and neurons are connected through so-called 
neurogliomal synapses that are located on MTs indicating 
another layer of resistance through connection with normal 
cells.6 Molecular mediators driving the MT network identi-
fied so far such as GAP43 and tweety-homolog 1 (TTYH1)7 
are also important in normal physiology of the CNS. Thus, 
the identification of more tumor-specific pathways that 
drive MT formation is of great interest in order to develop 
targeted therapies.
We recently showed by RNA sequencing of patient-
derived xenograft (PDX) tissue from laser capture micro-
dissected invasive and central tumor areas that the 
matricellular protein thrombospondin 1 (TSP1 or THBS1) 
was one of the most upregulated genes in infiltrative 
areas of GBM.8 TSP1 is a large trimeric calcium-binding 
molecule, which binds to diverse ligands and recep-
tors.9 In patient biopsies, both TSP1 and TGF-β (trans-
forming growth factor-beta) were expressed at high 
levels in GBM compared to low-grade gliomas (LGG).10 
In addition, TSP1 is an unfavorable prognostic marker for 
Importance of the Study
Microtubes (MTs) are important structural elements of 
GBM cells contributing to invasion and treatment resist-
ance. Thus, identifying molecular pathways that drive 
MT formation is crucial in developing new targeted treat-
ments. Our data show that TGF-β is a major pathway that 
distinguishes glioblastoma from chemosensitive oligo-
dendroglioma. In vitro, TGF-β stimulation induced MT 
formation in GBM cells by activating SMAD signaling 
and initiating Tsp1 expression. MT formation was inhib-
ited in vivo by blocking either Tsp1 expression or TGF-β 
signaling. In conclusion, we identified a new function 
of TGF-β in tumor development and also characterized 
its specific downstream signaling which might open up 













































































































GBM patients.11 The TGF-β18 but not the TGF-β212 canon-
ical pathway transcriptionally regulates TSP1 expression 
through SMAD3 binding to the THBS1 promoter. TSP1 si-
lencing inhibited cell invasion in vitro and in vivo, also in 
combination with anti-angiogenic therapy.8 Interestingly, 
TSP1 was also found to be regulated by calcium flux in 
several cancers.13
In the present study, we showed that TGF-β1 stimulation 
of GBM stem-like cell cultures promotes MT formation and 




Patient material was obtained from surgeries performed 
at the Haukeland University Hospital (Bergen, Norway). 
Written consent was obtained from patients with proced-
ures that were approved for the projects (project num-
bers 013.09 and 151825) by the Regional Ethics Committee 
(Bergen, Norway). In vivo experiments were conducted 
in accordance with the European Community for experi-
mental animal use guidelines (L358-86/609EEC) with proto-
cols approved by the Ethical Committee of INSERM (n° 
MESRI23570).
TCGA Data and GMT Files
For the “The Cancer Genome Atlas” (TCGA) dataset, 
RNAseqV2 median normalized data (RNA Seq V2 RSEM) 
and associated clinical data of the TCGA GBM and LGG 
cohorts were downloaded from cBioPortal (https://
www.cbioportal.org/). Details are described in the 
Supplementary Methods.
Cell Culture
The patient-derived GBM stem cell (GSC) lines P3,14 GG6 
and GG1615 are all derived from IDH wild-type (wt) GBM 
patients. GG16 was a giant cell glioblastoma.16 Cell lines 
were cultured in Neurobasal Medium, B27 supplement, 
Glutamax (NBM; Life Technologies), FGF2 (20 ng/ml), and 
EGF (20  ng/ml; Peprotech) in non-treated culture flasks 
(Nunc). U87, U251, and 293T cells were obtained from the 
American Type Culture Collection (Manassas, VA, USA) 
and maintained in DMEM supplemented with 10% fetal 
calf serum (FCS) and 1% glutamine. Medium was changed 
twice a week. All cell lines were grown at 37°C in a humidi-
fied atmosphere of 5% CO2.
In Vitro Experiments
2.5 × 104 cells from GSC lines were seeded on coverslips. 
Cells were treated with growth factors (10 ng/ml) and or 
inhibitors (10 µM) for 48 hours. For MT analysis and quan-
tification, 300 cells were counted in random microscopic 
fields.
Western Blots
Western blot of cultured cells was performed as described 
previously.8 Details are described in the Supplementary 
Methods.
Immunofluorescence Staining
Immunofluorescence staining was performed as previously 
described.8 Details are described in the Supplementary 
Methods.
Immunohistochemistry
Immunohistochemistry of paraffin-embedded formalin-
fixed tissue sections was performed as described pre-
viously.8 Details are described in the Supplementary 
Methods.
RNA Sequencing and Analysis
A total of 3 samples were assigned for each of the con-
trol (untreated) and treatment (TGF-β_48 hours) groups. 
Samples were processed for sequencing at Macrogen Inc, 
Korea where library preparation, sequencing, and quality 
control were performed. Details of the sample preparation 
and data analysis have been reported previously.17
GBM-Brain Organoid Co-Culture Ex Vivo 
Invasion Assay
For this assay, the preparation and culture of 18-day fetal 
brain organoids have been described in our previous 
work.18 For details, see Supplementary Methods.
In Vitro Calcium Imaging
Calcium signal spread across cells was carried out as pre-
viously described.19 Fluo-3-AM intensity was determined 
using the ImageJ z-axis profile function. Mean fluores-
cence intensity was determined from 20 time lapses per 
condition.
In Vivo Experiments
Ragγ2C−/− mice were housed with free access to food 
and water in a 12-hour light/dark cycle. Craniotomy and 
GBM spheroid implantation were done as previously de-
scribed.20 LY2109761 was administered orally at 50  mg/
kg twice daily (days 1-5 of each week) until the end of 
observation.
Statistics
All statistical analyses were performed on GraphPad Prism 
8.1.2. Data are displayed as mean ± SD. To compare one var-
iable between multiple groups, 1-way ANOVA with Tukey’s 
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between multiple groups, 2-way ANOVA with Tukey’s post 
hoc test was used. Differences were considered statisti-
cally significant when the P-value was below .05.
Results
TGF-β Signaling Is Upregulated in 
GBM Compared to 1p/19q Co-Deleted 
Oligodendroglioma
MTs are abundant in GBM, however uncommon in 1p/19q 
co-deleted oligodendroglioma. To identify new drivers 
of MT formation, we compared gene expression data 
from TCGA of IDH-wt tumors, the majority being GBM, to 
IDH-mutant and 1p/19q co-deleted oligodendroglioma. We 
found that TGFB1 and TGFB2 were among the significantly 
differentially expressed genes (Supplementary Table 1). 
Both TGFB1 and TGFB2 are highly upregulated in IDH-wt 
tumors compared to IDH-mutant and 1p/19q co-deleted tu-
mors (Figure 1a) and also upregulated in non–co-deleted 
(IDH-wt and IDH-mutant astrocytoma/GBM) vs co-deleted 
tumors (Supplementary Figure 1a). MT formation has been 
previously observed in particular at the invasive front of 
GBM.1 As TGF-β is a known driver of GBM invasion, we 
performed more detailed analyses. Interestingly, TGFB1 is 
located on chromosome 19q, which makes it an attractive 
candidate for MT formation. The differentially expressed 
genes of IDH-wt compared to IDH-mutant and 1p/19q 
co-deleted tumors (1.comparison) were then used to con-
























































































Mitochondrial complex IV LOF
Leucine rich repeat kinase inhibitor
Bromodomain inhibitor
Lipocalins GOF
TGF beta receptor inhibitor
HDAC inhibitor
Purinergic receptors P2Y GOF
Protein synthesis inhibitor
P38 MAPK inhibitor
Structural maintenance of chromosomes proteins LOF




Kinase anchoring proteins LOF
X linked mental retardation group 1 LOF





Bacterial DNA gyrase inhibitor
Tumor necrosis factor superfamily LOF
EIF Proteins LOF







































































































































































































































































































































































































































































































































































































































































































Fig. 1 TGF-β signaling is upregulated in GBM compared to IDH-mutant and 1p/19q co-deleted oligodendroglioma. Analysis of TCGA data com-
paring IDH-wt GBM and IDH-mutant and 1p/19q co-deleted oligodendroglioma. (a) TGFB1 and TGFB2 are upregulated in IDH-wt tumors. (b) GO 
term analysis reveals pathways related to extracellular matrix. (c) Heatmap of genes related to the top 20 GO terms where either TGFB1 or 
TGFB2 is present. (d) TGF-β responsive genes identified from the literature. (e) Analysis of drugs related to gene expression signature by con-
nectivity map reveals that TGF-β inhibitors are one of the top candidate drugs that inhibit IDH-wt GBM signature. Abbreviations: GBM, glioblas-














































































































The top regulated pathways were related to extracellular 
matrix, which are important pathways in tumor invasion 
(Figure 1b). We performed the same GO term analysis 
for non–co-deleted vs co-deleted tumors (2.comparison) 
where extracellular matrix pathways were also found, 
however, below a number of immune-related pathways 
(Supplementary Figure 1b). We then analyzed the com-
monly regulated pathways from these 2 comparisons in a 
Venn diagram revealing that the top common pathways in 
both were related to extracellular matrix (Supplementary 
Figure 1c, d). As MT formation is also highly dependent 
on extracellular matrix reorganization this could indicate 
an important role of TGF-β in this process. When focusing 
on the top 20 GO terms where either TGFB1 or TGFB2 was 
present in the gene list, the majority of associated genes in 
these pathways were upregulated in IDH-wt compared to 
1p/19q co-deleted tumors (Figure 1c). Next, we identified 
TGF-β responsive genes from the literature and showed 
that the majority of these genes are upregulated in IDH-wt 
compared to 1p/19q co-deleted tumors (Figure 1d). By 
using connectivity map from the Broad Institute,21 we ana-
lyzed drug candidates that would inhibit the expression 
signature of GBM (top 20 upregulated genes) compared 
to oligodendroglioma. One of the top drug candidates that 
came up in this screen were TGF-β inhibitors (Figure 1e) 
further highlighting an important role of the TGF-β pathway 
in promoting a GBM gene expression signature, when 
compared to chemosensitive oligodendroglioma.
TGF-β Promotes MT Formation in GBM Cell Lines 
In Vitro
To analyze the ability of different growth factors, including 
TGF-β, to induce cytoplasmic protrusions (MT-like struc-
tures), we stimulated P3 GBM cells with EGF, FGF, PDGFbb, 
TGF-β1, or TGF-β2. We observed that TGF-β1 was most ef-
ficient in promoting cellular protrusions when analyzing 
the percentage of cells with protrusions, number of protru-
sions per cell, and length of protrusions (Supplementary 
Figure 2a). Next, we stimulated 2 different GSC lines (P3 
and GG16) and 2 serum cultured GBM cell lines (U87 and 
U251) with TGF-β1 and analyzed morphological changes of 
the cells. A clear promotion of cellular protrusions by TGF-
β1 was observed in all cell lines (Figure 2a; Supplementary 
Figure 2b, c). To verify that these protrusions are MTs we 
stained the cells for GAP43, a known driver for MT forma-
tion as well as nestin and actin to visualize the cytoskel-
eton. The protrusions were rich in GAP43 which colocalized 
with actin and nestin (Figure 2a; Supplementary Figure 2b). 
This indicated that the protrusions are MTs as described 
previously.1,2 To further verify that cells are interconnected 
through MTs upon TGF-β1 stimulation, we performed 
Electron microscopy. We observed MTs extending from 
one cell and inserting into the membrane of a neighboring 
cell (Figure 2b). We analyzed and quantified the formation 
of MTs in detail by confocal microscopy using GAP43/
nestin or actin stainings. TGF-β1 stimulation increased the 
number of cells connected through MTs and importantly, 
also the length of MTs increased significantly (Figure 2c; 
Supplementary Figure 2b, c). To block TGF-β signaling, 
we used the TGF-β inhibitor LY2157299, which signifi-
cantly reduced pSMAD2 phosphorylation in P3 GBM cells 
(Supplementary Figure 3a). MT formation was significantly 
inhibited by LY2157299: the number of MTs per cell, the 
number of cells with MTs, and the length of MTs decreased 
substantially under treatment with LY2157299 in both P3 
and GG16 GBM cells (Figure 2c; Supplementary Figures 2c 
and 3b). In addition, we used an inducible shRNA to knock-
down TGFBRII, as stable knockdown was lethal to the cells 
(data not shown). The inducible construct confirmed the in-
hibition of MT formation in P3 cells (Supplementary Figure 
3c, d). As GAP43 has been shown to be a major structural 
element of MTs, we knocked down GAP43 with a shRNA 
to analyze if MT formation is blocked under TGF-β1 stim-
ulation. As expected, GAP43 knockdown prevented a sig-
nificant increase in the number and length of MTs under 
TGF-β1 stimulation (Supplementary Figure 4a, b) verifying 
that also in our culture system MT formation is dependent 
on GAP43 as described previously.1 To demonstrate that 
there is a functional connectivity between the tumor cells 
through the MT network, we performed calcium imaging 
using fluorescence indicator of intracellular calcium 3 
(Fluo-3).22 The intensity of the calcium wave was calculated 
for entire frames. Stimulation with TGF-β1 resulted in in-
creased calcium exchange between tumor cells through 
the MT network which was inhibited by LY2157299 (Figure 
2d; Supplementary Figure 5; Movies 1–4).
TGF-β Induced MT Formation Is Associated With 
Invasion
Among the GBM cell lines used in this work, we identified 
one GSC line, GG6, that did not show increase in MT for-
mation upon TGF-β1 stimulation. GG16, used as a control 
cell line, confirmed significant MT formation under stim-
ulation (Figure 3a). As MT formation is associated with 
invasion, we aimed to analyze the invasiveness of the 
nonresponder cell line GG6 in comparison with the TGF-
β1 responding GBM cell line GG16. We used a co-culture 
system of tumor spheroids with brain organoids from rat 
fetal brains to mimic the invasive process as described pre-
viously.18 Invasion was quantified as indicated in methods. 
The nonresponding cell line GG6 showed no significant 
invasion over a time period of 72 hours when co-cultured 
with brain organoids. In contrast, the TGF-β1 responding 
cell line GG16 showed substantial invasion into the 
organoid, which was not further increased by TGF-β1 stim-
ulation, however significantly reduced by TGF-β inhibition 
with LY2157299, indicating endogenous presence of TGF-β 
in the organoid microenvironment (Figure 3b). Upon im-
plantation of both cell lines in vivo, we verified a less in-
vasive phenotype of the nonresponder GG6 compared to 
the responder GG16 and a reduced MT density in nestin 
immunostained sections (Figure 3c). Importantly, we con-
firmed a reduced MT density in corresponding patient bi-
opsies from GG6 compared to GG16 stained with nestin 
antibodies (Figure 3c).
SMAD Activation Is Important for MT Formation
To identify major signaling mediators in TGF-β1 induced 
MT formation, we analyzed activation of downstream 



































































































































































































































































































































































































Fig. 2 TGF-β promotes MT formation and communication via calcium signaling in GBM cells. (a) Cellular protrusions induced by TGF-β1 in P3 
GBM cells are identified as MTs due to the expression of GAP43 which co-localizes with the cytoskeleton protein nestin. Scale bar 20 µm. (b) 
Scanning Electron Microscopy of P3 GBM cells shows that MTs connect 2 neighboring cells through cytoplasmic insertions. Higher magnifications 
of specific areas are provided as indicated. (c) TGF-β inhibitor LY2157299 inhibits MT formation in P3 and GG16 GBM cells. Immunofluorescence 
staining for F-actin is shown. Quantification of connections per cell and MT length is presented. Scale bar 10 µm. Statistically significant dif-
ferences of experimental groups compared to the control are shown on top of the respective bars. *P < .05; **P < .01; ***P < .001; ****P < 
.0001. (d) Calcium exchange between tumor cells is significantly increased upon TGF-β stimulation and inhibited by LY2157299 in P3 GBM cells. 
Fluorescence intensity represents the intensity of the calcium signal. The images were taken seconds following the laser injury as indicated. 
The bar graph represents the intensity at the time point as indicated by the dotted line in the curve diagram. Scale bar 30 µm. *P < .05; **P < .01. 
































































































































































































































































































































24 h 48 h 72 h
+ TGFβ + TGFβ+LY2157299
+ TGFβ
Fig. 3 TGF-β induced MT formation is associated with invasion. (a) GG6 GBM cells are not responding to TGF-β1 stimulation with increased MT 
formation in contrast to GG16 GBM cells. Immunofluorescence stainings for nestin are shown. Black and white pictures are presented to better 
visualize the MT network. Quantification of connections per cell and MT length is presented. Scale bar 20 µm. *P < .05; **P < .01; ***P < .001; 
****P < .0001. (b) Invasion of GG16 GBM cells into brain organoids is inhibited by LY2157299. TGF-β stimulation does not significantly increase 
invasion most likely due to the presence of TGF-β in the microenvironment. In contrast, nonresponder GG6 GBM cells do not show significant 
invasion into brain organoids. Immunofluorescence pictures of organoids after 72 h showing green fluorescent protein (GFP) signal (GBM cells). 
Higher magnifications of the invasive areas are provided below each organoid picture. Quantification of invasive cells is provided after 24, 48, and 
72 hours. Scale bar 70 µm (zoom 14 µm). Statistically significant differences of experimental groups compared to the control are shown on top of 
the respective bars. *P < .05; **P < .01; ***P < .001. (c) Immunohistochemical staining of GG6 and GG16 patient and xenograft GBM with nestin 
antibodies showing an extensive MT network in GG16, which is low to absent in GG6. Quantification of MT density is provided. Scale bar 100 µm 
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Fig. 4 SMAD activation is important for MT formation. (a) Double immunofluorescence stainings of pSMAD2/nestin, pMAPK/nestin, and pAkt/
nestin for P3, GG16, and GG6 cell lines are shown. Arrows indicate cells with MT formation. Arrowheads point to cells without MT formation. 













































































































GG16 cell lines by double immunofluorescence stainings 
with nestin (Figure 4a). Canonical (SMAD2/3) signaling cor-
related with MT formation in P3 and GG16, however, not in 
GG6 where also pSMAD2/3 activation levels were lower. 
The non-canonical pathways (MAPK and Pi3K/Akt) did not 
correlate with MT formation in all 3 cell lines (Figure 4a). 
Likewise, SMAD inhibition under TGF-β1 stimulation using 
the SMAD inhibitor SIS3 significantly reduced MT forma-
tion (Figure 4b). To further substantiate the role of SMAD2/3 
phosphorylation in MT formation, we immunostained con-
secutive sections from 7 GBM IDH-wt patient biopsies with 
pSMAD3 and nestin antibodies (Figure 4c; Supplementary 
Figure 6). Quantification of MT density in randomly 
selected pSMAD3+ and pSMAD3− areas was performed 
as described in the methods. For statistical analysis of the 
data, model selection was performed as indicated in the 
Supplementary Methods and Supplementary Table 2. The 
final model indicated a significant association between 
increased pSMAD3 expression and increased MT density 
when adjusting for overall cell density (T = 3.80, P = .0002).
Having demonstrated that pSMAD2/3 signaling is cru-
cial for MT formation downstream of TGF-β, we per-
formed co-immunoprecipitation of pSMAD2/3 signaling 
complexes in P3, GG6, and GG16 cell lines, followed by 
mass spectrometry to identify potential binding partners. 
Interestingly, P3 and GG16 samples clustered together, 
while GG6 samples were separated (Supplementary Figure 
7a). Despite these differences, the proteins in common be-
tween all 3 cell lines were related to TGF-β/SMAD signaling 
as also revealed by KEGG pathway analysis and GO bio-
logical function (Supplementary Figure 7, Supplementary 
Tables 8, 10, and 11). However, the SMAD2/3 proteome 
was very different between P3/GG16 and GG6. While P3 
and GG16 had 128 proteins in common, only 23 and 19 
proteins were shared between GG6/P3 and GG6/GG16, re-
spectively (Supplementary Figure 7, Supplementary Tables 
3–9). The proteins in common between P3 and GG16 were 
related to a number of pathways/biological processes 
(Supplementary Tables 12 and 13), while none could be 
identified for proteins of GG6. These results further con-
firm the similarity in TGF-β/SMAD signaling between re-
sponders in contrast to the nonresponder GG6.
TSP1 Is a Candidate for MT Formation 
Downstream of TGF-β1 and SMAD2/3
To identify targetable proteins involved in MT formation 
downstream of TGF-β1 and SMAD activation, we performed 
RNA sequencing of the responder cell lines GG16 and P3 
and the nonresponder cell line GG6 with and without TGF-β1 
stimulation (48 hours) to identify differences in gene ex-
pression profiles that would indicate potential candidates 
for MT formation downstream of TGF-β1/SMAD2/3 activa-
tion. The number of significantly upregulated genes under 
TGF-β1 stimulation varied substantially between the cell 
lines (Supplementary Table 14). In particular, GG16 showed 
only 60 upregulated genes, however, 34 of these genes 
were shared with P3, while only 1 gene was shared with 
the nonresponder cell line GG6 (Figure 5a; Supplementary 
Table 14). 19 genes were commonly upregulated in all 3 cell 
lines. Gene enrichment analysis showed that in all 3 cell 
lines, extracellular structure organization and extracellular 
matrix organization were the top regulated GOs (Figure 5b). 
When analyzing these GOs for common genes between 
the responders P3 and GG16, only 4 genes were found, 
while also 4 genes were in common between all 3 cell lines 
(Figure 5c; Supplementary Tables 15 and 16). Among the 4 
genes in common between the responders P3 and GG16, 
TSP1 (THBS1) was identified as an interesting candidate 
because (1) it also showed up in the previous analysis of 
TCGA data (Figure 1c, d); (2) it is upregulated in invasive 
tumor areas compared to the core in GBM xenografts,8 and 
(3)TSP1 is a downstream mediator of TGF-β1 and SMAD3 
signaling in GBM and important in tumor cell invasion.8 
Analysis of TCGA data also confirmed upregulation of 
TSP1 in IDH-wt GBM compared to IDH-mutant and 1p/19q 
co-deleted oligodendroglioma (Figure 5d).
TSP1 Is Activated by TGF-β1 and Mediates MT 
Formation
As described previously,8 Tsp1 expression is upregulated 
by TGF-β signaling through activation of the Tsp1 promoter 
by pSMAD3 (Figure 6a). Here, we confirmed that TSP1 pro-
tein expression was induced upon TGF-β1 stimulation in 
the responder cell lines GG16 and P3, while it was absent in 
the nonresponder cell line GG6 (Figure 6b; Supplementary 
Figure 8). We used a shRNA to knock down expression of 
TSP1 and analyzed MT formation under TGF-β1 stimula-
tion. ShTsp1 significantly reduced MT formation in P3 cells 
(connections per cell and MT length) when compared to 
scrambled control (Figure 6c). Likewise, overexpression of 
TSP1 in P3 cells showed increase in MT formation com-
pared to control cells (Supplementary Figure 9).
To verify that TGF-β and TSP1 are important players of 
MT formation in vivo, we performed intravital imaging 
of P3 cells implanted orthotopically in NOD/SCID mice. 
After 7-70 days, both inhibition of TGF-β by LY2157299 and 
knockdown of TSP1 by shRNA reduced the number of MTs 
per tumor cell in vivo compared to controls (Figure 6d).
under TGF-β1 stimulation. Immunofluorescence staining for F-actin is shown. Quantification of cells with MTs and MT length is presented. Scale 
bar 10 µm. *P < .05; **P < .01. (c) SMAD3 phosphorylation correlates with MT formation in GBM patient biopsies. Quantification of MT length on 
consecutive pSMAD3 immunostained and nestin immunostained sections of 1 patient (patient 2) is shown (see the Supplementary Methods for 
details). Images in the left column show original image data, images in the right column show visualizations of the quantifications. Black lines 
mark MTs, red outlines denote nuclei, and green outlines pSMAD3-positive nuclei. The graph shows the correlation of pSMAD3 expression with 
MT length using a linear mixed model. The surface shows the predicted value based on the fixed parameters of the linear mixed model. The 
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Fig. 5 TSP1 is a candidate for MT formation downstream of TGF-β1 and SMAD2/3. RNA sequencing data of P3, GG6, and GG16 GBM cells 
unstimulated and stimulated with TGF-β1 for 48 hours. (a) Venn diagram showing number of common and unique upregulated genes upon TGF-
β1 stimulation. Hypergeometric test for all overlaps, P < .0001. (b) Gene enrichment analysis showing upregulation of pathways related to ex-
tracellular matrix/structure in all 3 cell lines. (c) Venn diagram showing the number of common and unique regulated genes among the 3 cell 
lines from extracellular matrix and extracellular structure GOs. Hypergeometric test for GG6/GG16 P < .05, for all other overlaps, P < .0001. (d) 
Comparison of TSP1 expression in TCGA data between IDH-wt and IDH-mutant, 1p/19q co-deleted tumors. Abbreviations: GBM, glioblastoma; GO, 






































































































































































































































































Fig. 6 Inhibition of TSP1 reduces MT formation in vitro and in vivo. (a) Schematic figure showing upregulation of Tsp1 expression by TGF-β 
signaling through binding of pSMAD3 to the Tsp1 promoter. Tsp1 expression can be inhibited by LY2157299 or shRNA Tsp1. (b) Western blot of Tsp1 in 
P3 shControl and P3 shTsp1 with and without TGF-β1 stimulation. (c) MT formation is inhibited by shTsp1. Immunofluorescence staining for F-actin 
is shown. Quantification of connections per cell and MT length is presented. Scale bar 10 µm. *P < .05; **P < .01; ***P < .001. (d) Formation of MT 
network in vivo in the orthotopic P3-GFP GBM xenograft model was analyzed by intravital imaging. ShTsp1 and LY2157299 inhibit MT formation com-
pared to shcontrol. Immunofluorescence pictures of intravital imaging are shown. Quantification of MT number per tumor cell is presented. Scale 
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Discussion
In the present study, we identified a new molecular mech-
anism of MT formation in GBM. We showed that TGF-β1, a 
multifunctional cytokine, promotes MT formation in vitro 
and in vivo. MTs have been defined as major drivers of 
GBM invasion and resistance to standard treatments such 
as radiation and chemotherapy.1 Since this hallmark study, 
where the GAP43 protein was identified as a major struc-
tural protein of MTs, new and fundamental insights into 
detailed molecular mechanisms of MT formation are still 
lacking. In search of molecular drivers of MT formation, we 
performed a bioinformatics analysis comparing IDH-mutant 
1p/19q co-deleted vs IDH-wt tumors. We chose this starting 
point because MT formation is abundant in IDH-wt tumors 
while it is low to absent in IDH-mutant and co-deleted tu-
mors.1 This analysis brought our attention to TGF-β. Among 
other gene candidates, TGFB1 and TGFB2 are expressed at 
significantly lower levels in co-deleted tumors. Importantly, 
TGFB1 is located on chromosome 19q and very important 
in GBM invasion,23 which are additional justifications for its 
potential role in MT formation. TGF-β is a cytokine with mul-
tiple functions which are dependent on the cell type and its 
associated microenvironment.24 In GBM, TGF-β is well char-
acterized as a cytokine that promotes invasion, angiogen-
esis as well as suppression of the immune system.25 Thus, 
our results add an additional function of TGF-β to its diver-
gent roles in GBM development. We demonstrated exper-
imentally in different ways that TGF-β1 is important in MT 
formation: (1) by stimulation with TGF-β1; (2) by blocking of 
TGF-β activity using the inhibitor LY2157299 and an induc-
ible shRNA. As our study is among the first to analyze MT 
formation in vitro, we had to verify that the structures we 
analyzed are corresponding to the MTs which have been 
shown in vivo.1 We identified MTs in our culture system by 
demonstrating co-expression of major structural proteins 
of MTs such as nestin, actin, and GAP43. Nestin, a protein 
related to cellular stemness, has recently been identified as 
an important protein expressed in the GBM MT network in 
vivo.2 Thus, we used this marker in our study to identify and 
quantify MTs. Knockdown of GAP43, which significantly re-
duced MT formation under TGF-β1 stimulation, further cor-
roborated that the structures we analyzed in vitro are very 
similar to the MTs formed in vivo.
MTs connect tumor cells with each other forming a 
communicating network. To show that network formation 
is promoted by TGF-β1, we performed calcium imaging. 
As expected, calcium exchange increased upon TGF-β1 
stimulation and was inhibited by LY2157299. Network 
formation and increase in calcium exchange in GBM cells 
in vitro was also observed by da Silva et al using ROCK 
inhibition.19
The majority of our cell lines responded to TGF-β1 with 
increase in MT formation. Interestingly, we identified one 
cell line (GG6), which did not respond and also showed 
very limited invasive capacity upon TGF-β stimulation 
using ex vivo brain organoid co-cultures and in vivo 
xenografts. These results highlight that MT formation and 
invasion are highly connected as also demonstrated pre-
viously.1 Inhibition of TGF-β activity in GBM in a clinical 
setting has been unsuccessful so far.26,27 Reasons for 
these disappointing results may be the dose limitations 
due to the important physiological roles of TGF-β in the 
body and also the BBB which often impairs drug penetra-
tion.28 Thus, we aimed to further characterize downstream 
signaling of TGF-β inducing MT formation to reveal more 
cancer-specific downstream signaling. First, we identified 
the canonical SMAD2/3 signaling as being the most im-
portant downstream pathway and also showed in a pa-
tient setting that SMAD3 activation correlates with MT 
length in patient biopsies. Previously, SMAD2/3 signaling 
was shown to impact glioma invasion,15,29 whereas 
SMAD3 was defined as the main transcription factor regu-
lating invasion and TSP1 expression in GBM cells.8 To fur-
ther identify more specific downstream targets of TGF-β 
and SMAD signaling, we performed RNA sequencing 
and bioinformatics analysis of cell lines P3 and GG16 
(responding to TGF-β with MT formation) and compared 
the data to the nonresponder cell line GG6. TSP1 came 
up as an interesting candidate which was absent in the 
nonresponder GG6 as also verified by western blotting. 
Interestingly, we have previously shown that TSP1 is ac-
tivated by TGF-β signaling and specifically by SMAD3 
through a SMAD3 binding site in the TSP1 promoter.8 
We also demonstrated in this study that TSP1 promotes 
GBM invasion downstream of TGF-β and SMAD. Thus, as 
invasion and MT formation are linked to each other, we 
demonstrated that knockdown of TSP1 inhibited invasion 
and MT formation both in vitro and in vivo. TSP1 has a 
substantial interactome that is still not fully explored con-
sisting of extracellular matrix components, matricellular 
proteins, different receptors, proteases, and growth fac-
tors.8,30 Thus, TSP1 likely involves a potential network of 
additional proteins in MT formation/invasion, which need 
to be identified in future studies.
In conclusion, we identified TGF-β as a new mediator of 
MT formation through SMAD and Tsp1 signaling. Blocking 
this pathway might be an attractive strategy to treat GBM 
in the future.
Supplementary Material
Supplementary material is available at Neuro-Oncology 
online.
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